Daily Stock Analysis, ASND, Ascendis Pharma A/S, priceseries

Ascendis Pharma A/S. Daily Stock Analysis
Stock Information
Open
104.08
Close
105.56
High
105.88
Low
103.22
Previous Close
104.53
Daily Price Gain
1.03
YTD High
137.40
YTD High Date
Jan 3, 2022
YTD Low
102.00
YTD Low Date
Mar 3, 2022
YTD Price Change
-30.19
YTD Gain
-22.24%
52 Week High
178.71
52 Week High Date
Sep 3, 2021
52 Week Low
102.00
52 Week Low Date
Mar 3, 2022
52 Week Price Change
-35.70
52 Week Gain
-25.27%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 7. 2017
22.19
Mar 14. 2017
28.66
24 Trading Days
29.14%
Link
LONG
Jan 5. 2018
39.92
Jan 30. 2018
51.77
16 Trading Days
29.68%
Link
LONG
Jan 4. 2019
64.62
Jan 28. 2019
71.28
15 Trading Days
10.31%
Link
LONG
Oct 28. 2019
105.09
Nov 12. 2019
111.54
11 Trading Days
6.13%
Link
LONG
Dec 16. 2019
118.07
Jan 6. 2020
131.82
13 Trading Days
11.65%
Link
LONG
Sep 23. 2020
146.00
Oct 14. 2020
158.89
15 Trading Days
8.83%
Link
LONG
Nov 25. 2020
162.15
Dec 16. 2020
174.56
14 Trading Days
7.65%
Link
LONG
Aug 25. 2021
123.67
Sep 10. 2021
154.17
11 Trading Days
24.67%
Link
Company Information
Stock Symbol
ASND
Exchange
NasdaqGS
Company URL
http://www.ascendispharma.com
Company Phone
45 36 94 44 86
CEO
Michael Wolff Jensen
Headquarters
-
Business Address
TUBORG BOULEVARD 5, HELLERUP, DENMARK DK-2900
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001612042
About

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies to address markets with unmet medical needs. The company was founded by Jan Møller Mikkelsen in September 2006 and is headquartered in Hellerup, Denmark.

Description

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It has strategic collaborations with Sanofi and Genentech. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.